Bionano Genomics Reports Q2 2026 Financial Results

What Happened
Bionano Genomics, Inc. announced and filed a Current Report on Form 8‑K on August 10, 2026 reporting its financial results for the second quarter ended June 30, 2026. The company issued a press release with the results, which is attached to the 8‑K as Exhibit 99.1. The report was signed by Interim CEO Albert A. Luderer, Ph.D.

Key Details

• Filing date: August 10, 2026 (Form 8‑K, Item 2.02 – Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026.
• Exhibit included: Press release reporting the Q2 2026 results (Exhibit 99.1).
• Report signed by: Albert A. Luderer, Ph.D., Interim Chief Executive Officer. (Inline XBRL cover page included as Exhibit 104.)

Why It Matters
This 8‑K notifies investors that Bionano has publicly released its quarterly earnings information; investors should review the attached press release and any subsequent SEC filings for revenue, profit/loss, cash position, and any management commentary or guidance. The filing itself is a routine disclosure of quarterly results, but it is the primary source for the company’s latest operational and financial performance for Q2 2026.